A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight
Latest Information Update: 20 Feb 2026
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity; Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SURPASS-T1D-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 17 Feb 2026 Planned End Date changed from 1 May 2027 to 1 Dec 2026.
- 17 Feb 2026 Planned primary completion date changed from 1 May 2027 to 1 Nov 2026.
- 17 Feb 2026 Status changed from not yet recruiting to active, no longer recruiting.